Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
PMID: 34881075
It targets two appetite hormones instead of one, producing more weight loss in clinical trials: 22.5% of body weight over 72 weeks
Initiate appropriate supportive treatment according to the patient's clinical signs and symptoms
The follow-up pivotal trial (METAOD006 / OPTIONS) enrolled a larger cohort and failed to replicate statistically significant weight loss, which led Metabolic Pharmaceuticals to halt the formal drug development program in 2007
The molecules themselves are not villains
Hypertrophy + hyperplasia Animal-model research shows IGF-1 LR3 drives both fibre growth (hypertrophy) and new fibre formation (hyperplasia) - distinct from most anabolic agents
US$ 25.10
US$ 24.45
US$ 21.01
US$ 24.65
